Equities

Amplitude Surgical SA

Amplitude Surgical SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)3.24
  • Today's Change0.08 / 2.53%
  • Shares traded1.97k
  • 1 Year change-8.99%
  • Beta0.3662
Data delayed at least 15 minutes, as of Sep 20 2024 10:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amplitude Surgical SA is a France-based company engaged in the field of orthopedic surgeries. The Company offers the AMPLIVISION system, a computer navigation workstation and its related software, which is fully developed by the Company in collaboration with surgeons. Each implant is validated mechanically by creating models and running tests on simulators. Amplitude Surgical SAS relies on the expertise of its design offices and on scientific partnerships to internally design and develop its implants and automatic or computer-navigated instruments. It operates through ofab Orthopedie, a strategic industrial subcontractor

  • Revenue in EUR (TTM)104.05m
  • Net income in EUR43.23m
  • Incorporated2011
  • Employees416.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biosynex SA92.98m-37.12m43.44m575.00--0.3545--0.4672-3.64-3.649.1011.920.37041.167.34161,700.90-14.1814.90-17.5119.4152.8451.92-38.3014.611.03-28.000.3459---52.7024.40-337.76------
AbL Diagnostics SA5.61m54.36k44.48m19.00818.996.5762.077.920.00340.00340.34830.420.3703--1.42295,411.600.35873.240.58844.43----0.96858.811.87-47.510.3389---35.8474.86-95.08-49.30----
Median Technologies SA22.23m-22.98m73.70m242.00------3.32-1.26-1.261.21-0.56080.6289-19.613.5591,842.98-65.02-54.57-186.81-157.51104.50101.57-103.40-93.701.40--2.21---6.1028.52-13.70--38.38--
Affluent Medical SAS0.00-15.65m74.15m59.00--1.85-----0.5409-0.54090.001.020.00----0.00-26.83---31.42-------------24.430.328-------2.80------
Carmat SA5.53m-53.35m78.63m162.00------14.22-1.76-1.760.1787-0.64190.09321.611.2830,379.12-89.92-76.92-113.71-94.38-535.50---964.91-4,636.641.69-17.371.63--710.72---0.3502--16.99--
Amplitude Surgical SA104.05m43.23m151.75m416.003.511.602.771.460.90020.90022.171.970.39550.56528.83244,244.1016.21-0.365819.44-0.426779.4178.3040.98-1.081.210.41630.5395--14.44-0.0271993.58--7.11--
Lumibird SA203.56m7.13m215.68m1.05k26.971.118.811.060.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
Guerbet SA785.69m23.87m459.50m2.92k20.211.215.520.58481.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Data as of Sep 20 2024. Currency figures normalised to Amplitude Surgical SA's reporting currency: Euro EUR

Institutional shareholders

0.11%Per cent of shares held by top holders
HolderShares% Held
F�d�ral Finance Gestion SAas of 30 Apr 202453.79k0.11%
Groupama Asset Management SAas of 31 May 20240.000.00%
Data from 28 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.